Prognostic factors for chronic thrombocytopenia in systemic lupus erythematosus with immune thrombocytopenia

Soo Min Ahn,Eun-Ji Choi,Ji Seon Oh,Yong-Gil Kim,Chang-Keun Lee,Bin Yoo,Seokchan Hong
DOI: https://doi.org/10.1159/000540192
2024-07-29
Acta Haematologica
Abstract:Introduction: We aimed to identify the clinical characteristics and risk factors for chronic immune thrombocytopenia (ITP) in patients with systemic lupus erythematosus (SLE). Methods: We retrospectively reviewed patients diagnosed with SLE-associated ITP between January 2000 and December 2021. Patient characteristics were analyzed according to the progression of chronic thrombocytopenia. No response was defined as a platelet count < 30 ×109/L or less than double the baseline count after treatment. Factors associated with chronic ITP were evaluated by logistic regression analysis. Results: Among the 121 patients with SLE-associated ITP, 27 progressed to chronic ITP lasting more than one year after initial diagnosis. The median initial platelet count was significantly lower in patients with chronic thrombocytopenia than in those without the disease (16 vs. 51 × 109/L). Patients who did not achieve a response within one month of treatment exhibited a high probability of progressing to chronic ITP (55.6% vs. 22.3%, p <0.001). Multivariable analysis revealed that severe thrombocytopenia at baseline (<20 × 109/L) (adjusted odds ratio [aOR] = 13.628, 95% confidence interval [CI] = 3.976–46.791) and no response within one month (aOR=9.171, 95% CI=2.776–30.298) were significantly associated with the risk of progression to chronic ITP in patients with SLE. Approximately one-quarter of the patients with SLE-associated ITP progressed to chronic ITP. Conclusion: Severe thrombocytopenia, and failure to achieve a response within one month were risk factors for the development of chronic ITP in those patients.
hematology
What problem does this paper attempt to address?